Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Research Abstract |
This time, we succeeded in the full cloning of new molecular target C19ORF10 activated in hepatocellular carcinoma by the comprehensive gene analysis which used the SAGE library.C19ORF10 is a growth factor through PI3 K/Akt and MAPK/Erk1/2. Cancer cell growth was suppressed by adding the anti-C19ORF10 antibody. This result was submitted to International Journal of Cancer and published on Int J Cancer. 2011 Oct 1;129(7):1576-85. Furthermore, we created the ELISA plate to C19ORF10 serum-concentration measurement and examine to clinical application of C19ORF10.
|